425: Strive, Semler Scientific Merger Communication Filed

Strive, Inc. filed a Form 425 communication regarding its proposed business combination with Semler Scientific, Inc., including cautionary statements about forward-looking information.

Summary

• A communication was reposted on X.com by James Lavish, Board Member of Strive, Inc., on December 22, 2025.
• The communication pertains to Strive's proposed business combination with Semler Scientific, Inc.
• It includes extensive cautionary statements regarding forward-looking statements, highlighting inherent risks and uncertainties associated with the proposed transaction.
• Investors and stockholders of Semler Scientific are urged to read the Registration Statement on Form S-4 and the Information Statement/Proxy Statement/Prospectus for important information about both companies and the proposed transaction.

Sentiment

Score: 5

Explanation: The filing is a standard procedural communication for a proposed merger, heavily focused on legal disclaimers and risk factors, which is typical for such disclosures. It does not present new financial performance data or express overtly positive or negative sentiment beyond the standard legal requirements.

Positives

• The proposed transaction aims to deliver strategic benefits for the combined company.
• Anticipated financial benefits, including expected cost savings and strategic gains, are projected from the merger.

Negatives

• Integration of the two companies may prove more difficult, time-consuming, or costly than initially expected.
• The proposed transaction could be more expensive or take longer to complete than anticipated due to unexpected factors or events.
• Management's attention may be diverted from ongoing business operations and other opportunities during the merger process.
• Strive's issuance of additional shares of its Class A common stock in connection with the transaction will cause dilution for existing shareholders.
• There is a potential for adverse reactions from Strive's or Semler Scientific's customers, or changes to business or employee relationships, resulting from the announcement or completion of the proposed transaction.
• Changes in Strive's or Semler Scientific's share price may occur before the closing of the transaction.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the right of one or both companies to terminate the merger agreement.
• The possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not received or satisfied on a timely basis or at all.
• The outcome of any legal proceedings that may be instituted against Strive, Semler Scientific, or the combined company.
• The possibility that the anticipated benefits of the proposed transaction, including anticipated cost savings and strategic gains, are not realized when expected or at all.
• Risks associated with changes in, or problems arising from, implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets.
• General economic and market conditions, interest and exchange rates, monetary policy, and laws and regulations and their enforcement.
• The possibility that the integration of the two companies may be more difficult, time-consuming, or costly than expected.
• The possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events.
• The diversion of management's attention from ongoing business operations and opportunities.
• Dilution caused by Strive's issuance of additional shares of its Class A common stock in connection with the proposed transaction.
• Potential adverse reactions of Strive's or Semler Scientific's customers or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction.
• Changes in Strive's or Semler Scientific's share price before closing.
• Other factors that may affect future results of Strive, Semler Scientific, or the combined company, including unknown or unpredictable factors.

Future Outlook

The outlook and expectations of Strive and Semler Scientific regarding the proposed transaction include anticipated strategic and financial benefits, the timing of the closing, and the ability to successfully integrate the combined businesses. However, these forward-looking statements are subject to significant risks and uncertainties, and actual results could differ materially from projections.

Management Comments

• James Lavish, Board Member of Strive, Inc., reposted the communication on X.com on December 22, 2025, in connection with the proposed business combination.

Industry Context

na

Legal Proceedings

• The outcome of any legal proceedings that may be instituted against Strive or Semler Scientific or the combined company could materially affect results.

Stakeholder Impact

• Shareholders of Strive may experience dilution due to the issuance of new Class A common stock.
• Shareholders of Semler Scientific are required to approve the proposed transaction.
• Customers of both Strive and Semler Scientific may have adverse reactions or changes to their business relationships.
• Employee relationships at both companies could be affected by the proposed transaction.

Next Steps

• Strive has filed a Registration Statement on Form S-4 to register the Class A common stock to be issued in connection with the proposed transaction.
• A definitive Information Statement/Proxy Statement/Prospectus was sent to the stockholders of Semler Scientific to seek their approval of the proposed transaction.
• Investors and stockholders of Semler Scientific are urged to read the Registration Statement and Information Statement/Proxy Statement/Prospectus, and any other relevant documents filed with the SEC, before making any voting or investment decision.
• The proposed transaction is subject to various closing conditions.

Key Dates

Keywords

Strive, Semler Scientific, merger, business combination, SEC filing, Form 425, forward-looking statements, risk factors, corporate governance, Bitcoin treasury, digital assets, stock issuance, dilution